At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BLTE Belite Bio, Inc.
Pre-Market Trading 12-23 08:31:37 EST
64.12
+0.68
+1.07%
盘前63.21
-0.91-1.42%
07:45 EST
High65.90
Low62.38
Vol57.49K
Open63.90
D1 Closing63.44
Amplitude5.56%
Mkt Cap1.98B
Tradable Cap829.72M
Total Shares30.88M
T/O3.70M
T/O Rate0.44%
Tradable Shares12.94M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Lin Bioscience Receives U.S. FDA Fast Track Designation for Lbs-007
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.